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A B S T R A C T   
Objective: Neuropsychiatric symptoms are frequent in obese individuals. Mounting evidence suggests that 
adiposity-related inflammation contributes to this effect. This study assessed the relationship between adiposity, 
neuropsychiatric symptom dimensions and systemic inflammation in subjects stratified by body-mass-index 
(BMI). 
Methods: The study included 165 subjects, of whom 70 were very severely obese (BMI ≥ 40 kg/m2), 50 severely 
obese (BMI: 35–39.99 kg/m2), 21 overweight or moderately obese (BMI: 25–34.9 kg/m2), and 24 lean (BMI < 25 
kg/m2). Depressive symptoms were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) 
and the Mini-International Neuropsychiatric Interview (MINI). Fatigue and general neurobehavioral symptoms 
were assessed using the Multidimensional Fatigue Inventory (MFI) and Neurotoxicity Rating Scale (NRS) 
respectively. Serum levels of the inflammatory markers, high-sensitive (hs) CRP and hsIL-6, were determined by 
ELISA. 
Results: Severely obese subjects exhibited higher MADRS, MFI and NRS scores and were more frequently afflicted 
with current diagnosis of major depression than lean participants. Scores on psychometric scales were also 
increased in very severely obese subjects, although to a lesser extent. Alterations in neuropsychiatric dimensions 
were highly inter-related. HsCRP was significantly increased in subjects with severe or very severe obesity, while 
hsIL-6 was augmented in all obese groups. Overall, increased neuropsychiatric comorbidity was associated with 
greater systemic inflammation, notably hsCRP. 
Conclusion: Obesity is characterized by an increased prevalence of inter-related neuropsychiatric symptoms 
together with low-grade systemic inflammation augmenting with adiposity. The association between adiposity, 
systemic inflammation and neuropsychiatric alterations supports the contribution of adiposity-related inflam-
matory processes to neuropsychiatric comorbidities in obesity. These data suggest that consideration of adiposity 
characteristics may help identifying subjects at increased risk for neuropsychiatric comorbidity.   
1. Introduction 
Obesity is considered the pandemic of the 21st century, representing 
an important societal and economic burden associated with a greater 
risk of morbidity and mortality (Blüher, 2019). Its prevalence has 
dramatically increased during the last decades, with more than 650 
million adults being obese worldwide in 2016 according to the last 
World Health Organization (WHO) estimates. The most commonly used 
measure of obesity is the Body Mass Index (BMI), calculated as the 
weight (kg) divided by the square of the height (m). Based on WHO 
criteria, individuals with a BMI ≥ 30 kg/m2 are considered as being 
obese, and individuals with a BMI between 25 and 29.9 kg/m2 are 
considered as being overweight or preobese. Obesity is further sub-
divided into severity degrees/classes, corresponding respectively to 
obesity class I (moderate obesity; 30 ≤ BMI ≤ 34.9 kg/m2), obesity class II 
(severe obesity; 35 ≤ BMI ≤ 39.9 kg/m2) and obesity class III (very severe/ 
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massive obesity; BMI ≥ 40 kg/m2). Higher degrees of obesity are believed 
to be associated with an increased risk of comorbidities, including type-2 
diabetes and cardiovascular diseases (Pantalone et al., 2017). 
Neuropsychiatric complications are also frequent in obese subjects. 
Accordingly, the prevalence of depression is significantly increased in 
the obese and obesity represents by itself a potent risk factor for the 
development of depressive disorders in longitudinal cohort studies 
(Lasselin and Capuron, 2014; Onyike et al., 2003; Herva et al., 2006). 
The occurrence of depressive symptoms in obese subjects represents a 
major concern as it strongly impacts quality of life, compromises 
adherence to treatment and weight management programs and is asso-
ciated with an increased risk of death by suicide (Mazzeschi et al., 2012; 
Mather et al., 2009). Data from epidemiological surveys indicate that 
the relationship between obesity and depression is particularly strong in 
higher degrees of obesity; with subjects afflicted with severe or very 
severe obesity exhibiting greater rates of depression than subjects with 
overweight or moderate obesity (Onyike et al., 2003; Zhao et al., 2009). 
In line with this, results from a meta-analysis show that being obese 
significantly increases the risk of depression, notably in women with 
severe obesity (Jung et al., 2017). Fatigue, sleep disturbances and 
cognitive alterations are also frequently reported in obese subjects (Zhao 
et al., 2009). Whether these alterations are connected in some ways to 
depressive symptoms or, in contrast, develop in distinct populations of 
obese subjects remains to be investigated. 
The link between obesity and neuropsychiatric comorbidity likely 
relies on mechanisms that are shared by both conditions (Huet et al., 
2019; Milaneschi et al., 2019). Among those mechanisms, adiposity- 
related inflammation appears critical as mounting evidence supports 
the role of inflammatory processes in neuropsychiatric symptoms in 
obese subjects (Capuron et al., 2017). Obesity is characterized by a 
chronic low-grade inflammatory state that originates primarily from the 
adipose tissue in which adipocytes and infiltrated immune cells secrete 
inflammatory factors (Hotamisligil, 2017; Lasselin et al., 2014). 
Accordingly, the inflammatory state of the visceral adipose tissue was 
found to correlate with circulating levels of inflammatory markers in 
subjects with obesity (Lasselin et al., 2014). Alterations in gut perme-
ability and gut microbiota composition are also believed to contribute to 
the obesity-related inflammatory state, notably by sustaining inflam-
mation in adipocytes (Cani et al., 2012; Hersoug et al., 2016). Increased 
blood concentrations of inflammatory markers, including C-reactive 
protein (CRP) and interleukin-6 (IL-6), have been repeatedly reported in 
obese subjects (Park et al., 2005; Capuron et al., 2011; Delgado et al., 
2018). Interestingly, those markers significantly correlated with obesity 
and adiposity indices, such as BMI, waist circumference, and fat distri-
bution (Park et al., 2005; Capuron et al., 2011). 
A large database has been developed that substantiates the role of 
chronic inflammatory processes in the physiopathology of depression 
and neuropsychiatric symptoms (Capuron and Miller, 2011; Dantzer 
et al., 2008; Raison et al., 2006). Accordingly, it is likely that adiposity- 
related chronic inflammation contributes to neuropsychiatric comor-
bidities in obesity. Consistent with this scenario, we found that systemic 
inflammation significantly correlates with emotional distress and 
depressive symptoms in severely obese subjects (Capuron et al., 2011; 
Delgado et al., 2018). Interestingly, similar associations were reported 
with respect to obesity-related cognitive alterations (Lasselin et al., 
2016). Supporting further the hypothesis that inflammation represents a 
key mediator of neuropsychiatric comorbidity in obesity, linear re-
lationships were measured between obesity grades and levels of circu-
lating inflammatory markers (Nguyen et al., 2009); in line with findings 
reporting greater neuropsychiatric symptoms in severe degrees of 
obesity (Lasselin and Capuron, 2014; Onyike et al., 2003; Herva et al., 
2006; Zhao et al., 2009; Jung et al., 2017). Altogether, these data sug-
gest a preferential association of neuropsychiatric comorbidities with 
higher degrees of obesity, probably due to an increased activation of 
adiposity-related inflammatory processes. 
The aim of the present study was to provide a detailed 
characterization of neuropsychiatric symptom profiles and their rela-
tionship with adiposity-related inflammatory status in a sample of 
subjects stratified by BMI. 
2. Methods 
2.1. Study participants 
A total of 165 participants were recruited. Since depressive symp-
toms were shown to be more prevalent in severe and very severe obesity 
in epidemiological studies (Onyike et al., 2003), recruitment of in-
dividuals from these obesity classes was privileged. Accordingly, fifty 
participants with severe obesity (BMI: 35–39.99 kg/m2) and seventy 
participants with very severe obesity (BMI ≥ 40 kg/m2) were included. 
Additionally, a group of twenty-one participants with overweight or 
moderate obesity (BMI: 25–34.9 kg/m2) and a group of twenty-four 
healthy lean participants (BMI < 25 kg/m2) were included for 
comparative purposes. Obese subjects were recruited from the services 
of digestive and parietal surgery of two private clinics (Tivoli and Jean- 
Villar) in Bordeaux, France. Non-obese participants were either enrolled 
from the same clinics as obese subjects or through public 
advertisements. 
For all study participants, exclusion criteria were: age > 75 years old; 
acute or chronic inflammatory conditions (other than obesity or obesity- 
related comorbidities for the groups of obese subjects); current treat-
ment with antidepressants or any other psychotropic drug; current 
treatment with anti-inflammatory agents; current diagnosis of psychi-
atric disease (except for major depression); and/or severe medical 
illness. The study was approved by the Institutional Ethics Committee 
for the Protection of Persons (CPP Bordeaux, France). All participants 
provided written informed consent after reading a complete description 
of the study. 
2.2. Clinical and neuropsychiatric assessments 
Socio-demographic (age, gender) and anthropometric variables 
(BMI, weight) were collected in all participants. Psychiatric antecedents, 
treatments, obesity history and obesity-related comorbidities, including 
type-2 diabetes, hypertension (HTA), dysthyroidism, obstructive sleep 
apnea (OSA) were also gathered. 
Depressive symptoms were assessed using the Montgomery-Asberg 
Depression Rating Scale (MADRS), a clinician administered scale that 
includes 10 items scored 0 to 6 with higher scores indicating greater 
symptom severity (Montgomery and Åsberg, 1979). Diagnosis of current 
major depressive disorder (MDD) was determined during a semi- 
structured interview with a trained clinician using the MINI- 
International Neuropsychiatric Interview (MINI) according to DSM 
criteria (Sheehan et al., 1998). 
Fatigue symptoms were assessed using the Multidimensional Fatigue 
Inventory (MFI), a 20-item self-report measuring five dimensions of 
fatigue including general fatigue, physical fatigue, mental fatigue, 
reduced activity and reduced motivation. Each dimension contains four 
items scored 1 to 5 with higher scores reflecting higher severity (Smets 
et al., 1995). 
The Neurotoxicity Rating Scale (NRS), a 39-item self-report vali-
dated in inflammatory conditions, was used to assess general and neu-
robehavioral symptoms (Valentine et al., 1995). Items on the scale are 
scored 0 “not present” to 4 “extremely severe”. As previously described, 
NRS symptoms were grouped into four specific symptom dimensions for 
data analysis, including the dimensions of sickness (tiredness, fever, sick 
feeling, body aches, joint/muscle pain, headaches), cognitive symptoms 
(indecisiveness, distractibility, episodes of confusion, word-finding 
problems, memory impairment), anxiety symptoms (anxiety, tension, 
irritability, agitation, worries about health) and sleep problems (diffi-
culty getting to sleep or staying asleep, sleeping too much) (Capuron 
et al., 2002, 2011). An average score was calculated per dimension to 
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homogenize scores across all dimensions. 
2.3. Biological measurements 
Fasting blood samples were collected the same day as neuropsychi-
atric assessments for the measurement of serum concentrations of high- 
sensitive (hs)CRP and hsIL-6. After 30–45 min at room temperature, 
samples were centrifuged (3200 rpm, 10 min at 4 ◦C) and sera were 
stored at − 80 ◦C until the assays. Concentrations of inflammatory 
markers were determined by enzyme-linked immunosorbent assay 
(ELISA) according to the manufacturer’s specifications (hsCRP: CYT298, 
Millipore, Billerica, Massachusetts; hsIL-6: R&D Systems, Minneapolis, 
Minnesota). Intra-/inter-assay variability was ±4.6/6.0% for hsCRP, 
and ±7.4/7.8% for hsIL-6. Sensitivities were 0.20 ng/mL for hsCRP and 
0.039 pg/mL for hsIL-6. 
2.4. Data analysis 
Clinical and neuropsychiatric variables were assessed using the Chi- 
square test (χ2) for categorical variables and analyses of covariance 
(ANCOVA), controlling for age, gender and comorbidities (type-2 dia-
betes, dysthyroidism, HTA, OSA) for continuous variables. Post-hoc 
comparisons were performed using the Tukey test of significance. Of 
note, data for self-reports (MFI and NRS) were missing in three partic-
ipants who did not fully complete the questionnaires. 
Raw values for hsCRP and hsIL-6 were log-transformed because of 
non-normality of the distribution, as determined by the Shapiro-Wilk 
test. Extreme values for hsCRP and/or hsIL-6 (>3 SD above the mean) 
were obtained in three participants. Accordingly, data from these sub-
jects were considered as outliers and were excluded from data analyses 
performed on biological markers. Associations between obesity indices, 
scores on neuropsychiatric scales and biological variables were assessed 
using Bravais-Pearson correlations. Further, the relationship between 
neuropsychiatric variables was assessed using a principal component 
analysis (PCA) in the whole sample under study to assess the intercon-
nection between neuropsychiatric symptoms and to potentially extract 
reduced and/or specific symptom dimensions. Statistical analyses were 
performed using XLStat software (StatSoft). Probabilities were two- 
tailed with the level of significance set at p < 0.05. 
3. Results 
3.1. Characteristics of study participants 
Characteristics of study participants are shown in Table 1. There was 
no significant differences between groups in terms of age and gender (F 
(3,161) = 1.11, p = 0.35; χ2 = 3.49, p = 0.32). As expected, BMI and 
weight were different across groups (F(3,161) = 438.1, p < 0.0001 and F 
(3,161) = 156.4, p < 0.0001, respectively). Similarly, obesity-related 
comorbidities, in particular type-2 diabetes (χ2 = 8.60, p = 0.04) and 
OSA (χ2 = 24.89, p < 0.0001) were more frequent in subjects with very 
severe obesity and in subjects with severe and very severe obesity, 
respectively. Interestingly, the proportion of subjects with early onset 
obesity (obesity since childhood/adolescence) was greater in the group 
of very severe obesity. 
3.2. Neuropsychiatric symptoms 
3.2.1. Depressive symptoms 
As shown in Fig. 1A, the prevalence of current MDD according to 
DSM criteria was significantly different across groups (χ2 = 13.15, p <
0.01), with subjects with severe and very severe obesity exhibiting 
higher prevalence rates than lean controls. Albeit severely obese sub-
jects tended to show increased MDD rates compared to very severely 
obese participants, this difference did not reach significance level. 
Consistent with these data, ANCOVA controlling for age, gender and 
comorbidities revealed significant differences in MADRS total scores 
between groups (F(3,158) = 4.67, p < 0.01). In particular, subjects with 
severe obesity exhibited significantly higher MADRS scores than lean 
controls (p < 0.01) and participants with overweight or moderate 
obesity (p < 0.05) (Fig. 1B). Analysis performed on individual items of 
the MADRS scale indicated that this difference was primarily apparent 
for items of apparent sadness, inability to feel, pessimistic thoughts and 
suicidal thoughts where, overall, subjects with severe obesity exhibited 
higher scores (Table 2). 
3.2.2. Fatigue symptoms 
MFI total scores were significantly different across groups (F(3,155) 
= 4.92, p < 0.01), with subjects with severe and very severe obesity 
exhibiting overall higher MFI total scores than lean controls (Table 3). 
Analyses on fatigue symptom dimensions revealed that subjects with 
severe obesity exhibited greater scores in each dimension of fatigue 
when compared to lean controls. All obese groups (from overweight to 
very severe obesity) exhibited higher scores of physical fatigue 
compared to lean controls. 
3.2.3. Other general and neurobehavioral symptoms 
Overall, NRS total scores were significantly different across groups (F 
(3,154) = 5.87, p < 0.001), with subjects with severe obesity and very 
severe obesity exhibiting higher scores than lean controls and subjects 
with overweight or moderate obesity (Table 3). This difference was 
particularly apparent in the NRS dimensions of sickness. 
In order to assess the relationship between neuropsychiatric symp-
tom dimensions, a PCA was performed on neuropsychiatric scores 
(including MADRS total scores, MFI and NRS dimension scores) in the 
whole population under study. Results indicated that neuropsychiatric 
scores were highly interconnected as they all loaded in one single factor 
(eigenvalue = 5.86) explaining 58.6% of the variance and interpreted as 
Table 1 



















Sample size, n 24 21 50 70  
Age, years (SD) 44.1 
(14.7) 

































Comorbidities      
T2D, n (%) 0 (0) 0 (0) 1 (2) 8 (11)b,d 0.04 
HTA, n (%) 2 (8) 4 (19) 7 (14) 13 (19) 0.64 
Dyst, n (%) 3 (13) 2 (10) 4 (8) 6 (9) 0.93 
OSA, n (%) 0 (0) 3 (17) 18 (41)b 35 (53)b, 
d 
<0.001 
Continuous variables are presented as mean and standard deviation and 
compared using one-way ANOVA, whereas categorical variables are presened as 
n (%) and compared by chi-square test. Post-hoc comparisons were performed 
using the Tukey test of significance. a p < 0.001 vs lean controls; b p < 0.01 vs 
lean controls; c p < 0.001 vs overweight or moderate obesity; d p < 0.01 vs 
overweight or moderate obesity; e p < 0.001 vs severe obesity. *Early onset 
obesity was considered when obesity was already present at childhood/ 
adolescence (this information was missing in 2 subjects with overweight or 
moderate obesity and 4 subjects with severe obesity). Abbreviations: BMI: Body 
Mass Index; T2D: type-2 diabetes; HTA: Hypertension; Dyst: Dysthyroidism; 
OSA: Obstructive Sleep Apneas; SD: standard deviation. 
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a neuropsychiatric comorbidity factor. Neuropsychiatric comorbidity, 
indicated by positive scores on this component, was observed in 17.4% 
of lean participants and in 36.8% of subjects with overweight or mod-
erate obesity. This proportion was increased up to 56% and 44.3% in 
subjects with severe and very severe obesity respectively. 
3.3. Obesity-related systemic inflammation and its relationship with 
neuropsychiatric symptoms 
Circulating concentrations of inflammatory markers across BMI 
groups are depicted in Fig. 1C-D. ANCOVA controlling for age, gender 
and comorbidities indicated a significant difference in hsCRP levels 
across groups (F(3,155) = 59.44, p < 0.001). In particular, subjects with 
severe and very severe obesity were found to exhibit higher levels of 
hsCRP compared to lean controls and subjects with overweight or 
moderate obesity (all p < 0.001). No difference was found between 
subjects with severe and very severe obesity and between lean controls 
and subjects with overweight or moderate obesity with respect to hsCRP 
levels. Similarly, levels of hsIL-6 were significantly different across 
groups (F(3,155) = 12.45, p < 0.001), with obese subjects, whatever the 
degree of obesity, exhibiting higher concentrations of this marker than 
lean controls. In line with this, BMI was highly correlated with hsCRP (R 
Fig. 1. Depressive symptoms and circulating concentrations of inflammatory markers in obese subjects and lean participants. Panels A & B. Prevalence of 
current MDD according to DSM criteria (panel A) and MADRS total scores (panel B) in the study population. Analyses were performed using chi-square test for MDD 
prevalence and ANCOVA controlling for age, gender and comorbidities for MADRS total scores. Panels C & D. HsCRP (panel C) and hsIL-6 (panel D) concentrations in 
the study population. Values were log-transformed for statistical analysis but displayed as raw value geometric means for information and readability purposes. 
Analyses were performed using ANCOVA controlling for age, gender and comorbidities. Post-hoc comparisons were performed using the Tukey test of significance. 
Data are shown as mean (+SEM). * p < 0.05; ** p < 0.01; *** p < 0.001. Abbreviations: CTRL: lean participants; mOB: subjects with overweight or moderate obesity; 
sOB: subjects with severe obesity; vsOB: subjects with very severe obesity; MADRS: Montgomery-Asberg Depression Rating Scale; MDD: major depressive disorder; 
hsCRP: high-sensitive C-reactive protein; hsIL-6: high-sensitive interleukin-6; DSM: Diagnostic and Statistical Manual of Mental Disorders; SEM: standard error of 
the mean. 
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= 0.633, p < 0.001) and hsIL-6 (R = 0.428, p < 0.001) in the whole 
population under study and in the obese groups only (R = 0.443, p <
0.001 and R = 0.216, p < 0.05 respectively). In the whole population 
under study, levels of hsCRP and hsIL-6 were highly correlated (R =
0.493, p < 0.001). The association remained significant when the 
analysis was restricted to subgroups of obese subjects (R = 0.349, p <
0.001). 
As shown in Table 4, hsCRP and hsIL-6 were individually correlated 
with neuropsychiatric scores in the whole population under study. 
Correlations were more frequent with hsCRP that was significantly 
associated with MADRS total scores, MFI scores of physical fatigue, NRS 
total scores, and NRS scores of sickness and anxiety. Significant corre-
lations were also measured between hsIL-6 and NRS total scores and 
scores on the MFI dimensions of physical fatigue and reduced activity. 
Similarly, scores on the neuropsychiatric comorbidity factor were signifi-
cantly correlated with hsCRP. In line with these data, cross-sectional 
analyses comparing participants afflicted or not with neuropsychiatric 
comorbitidity (score either negative or positive on the neuropsychiatric 
comorbidity factor) indicated greater levels of hsCRP and hsIL-6 in sub-
jects with neuropsychiatric comorbidity (Table 5). These results 
remained significant when comparisons were adjusted for age, gender 
and comorbidities. 
4. Discussion 
To our knowledge, the present study is the first to examine the as-
sociation between incrementing degrees of adiposity, markers of 
Table 2 
MADRS item scores across BMI classes.   
Lean Controls 
BMI < 25 




Very Severe Obesity 
BMI ≥ 40 
p 
MADRS items, mean (SD) 
1.Apparent sadness 0.3 (0.6) 0.5 (0.7) 0.9 (1.2)b 0.4 (0.8)c  0.005 
2.Reported sadness 0.6 (0.9) 0.7 (1.0) 1.3 (1.3) 0.9 (1.1)  0.04 
3.Inner tension 1.1 (1.1) 1.0 (1.0) 1.5 (1.1) 1.2 (1.0)  0.24 
4.Reduced sleep 0.7 (1.2) 0.9 (1.3) 1.3 (1.4) 1.0 (1.3)  0.28 
5.Reduced appetite 0.1 (0.3) 0.0 (0.0) 0.2 (0.6) 0.3 (0.8)  0.14 
6.Concentration difficulties 0.5 (1.0) 0.3 (0.6) 0.8 (1.1) 0.6 (1.1)  0.31 
7.Lassitude 0.5 (0.8) 0.5 (0.9) 1.1 (1.3) 1.0 (1.3)  0.18 
8.Inability to feel 0.3 (0.6) 0.5 (1.0) 1.1 (1.3)b 0.5 (0.8)c  0.005 
9.Pessimistic thoughts 0.8 (0.9) 1.1 (1.3) 1.7 (1.2)a 1.4 (1.3)  0.01 
10.Suicidal thoughts 0.2 (0.4) 0.3 (0.5) 0.6 (0.8)a 0.5 (0.7)  0.009 
Analyses were performed using ANCOVA controlling for age, gender and comorbidities. Post-hoc comparisons were performed using the Tukey test of significance. a p 
< 0.01 vs lean controls, b p < 0.05 vs lean controls, c p < 0.05 vs severe obesity. Abbreviations: BMI: Body Mass Index; MADRS: Montgomery-Asberg Depression Rating 
Scale; SD: standard deviation. 
Table 3 
MFI and NRS scores across BMI classes.   
Lean Controls BMI < 
25 
Overweight or Moderate Obesity BMI: 
25–34.9 
Severe Obesity BMI: 
35–39.9 
Very Severe Obesity BMI ≥ 
40 
p 
MFI scores, mean (SD)* 
Total score 38.9 (11.6) 46.3 (12.6) 52.9 (17.2)a 48.1 (14.8)  0.003 
General fatigue 9.8 (3.7) 11.6 (3.7) 12.3 (4.3) b 11.2 (3.9)  0.05 
Physical fatigue 7.9 (3.2) 11.1 (4.0)b 12.8 (4.4) a 12.3 (4.1)a  <0.001 
Mental fatigue 6.8 (2.3) 7.3 (2.8) 8.9 (3.6)b 7.7 (3.5)  0.03 
Reduced activity 7.5 (3.3) 9.2 (3.4) 10.1 (4.2)b 9.1 (3.5)  0.05 
Reduced motivation 6.9 (2.4) 7.1 (2.6) 8.8 (3.7) b 7.9 (3.2)  0.03 
NRS scores, mean (SD)* 
Total score 17.5 (12.1) 25.0 (15.7) 39.4 (21.9)a 35.2 (22.2)b  <0.001 
Cognitive 
alterations 
0.5 (0.5) 0.6 (0.6) 0.8 (0.7) 0.7 (0.7)  0.22 
Altered sleep 0.8 (0.9) 0.9 (0.6) 1.4 (1.1) 1.0 (0.9)  0.07 
Sickness symptoms 0.7 (0.5) 1.1 (0.6) 1.6 (0.8)a 1.4 (0.8)a  <0.001 
Anxiety 1.0 (0.8) 0.9 (0.6) 1.4 (0.8) 1.4 (0.7)  0.05 
Analyses were performed using ANCOVA controlling for age, gender and comorbidities. Post-hoc comparisons were performed using the Tukey test of significance. a p 
< 0.01 vs lean controls, b p < 0.05 vs lean controls. *MFI and NRS scores were missing for 1 lean control and 2 subjects with overweight or moderate obesity. Ab-
breviations: BMI: Body Mass Index; MFI: Multidimensional Fatigue Inventory; NRS: Neurotoxicity rating Scale; SD: standard deviation. 
Table 4 
Relationship between systemic inflammation and neuropsychiatric symptoms.   
Log hsCRP Log hsIL-6 
Depressive Symptoms     
MADRS total score 0.242** 0.101 
Fatigue     
MFI total score 0.124 0.151 
General fatigue  0.048  0.055 
Physical fatigue  0.228**  0.232** 
Mental fatigue  0.132  0.107 
Reduced activity  0.045  0.158* 
Reduced motivation  0.035  0.048 
General and Neurobehavioral Symptoms     
NRS total score 0.264*** 0.165* 
Cognitive alterations  0.137  0.150 
Altered sleep  0.151  0.101 
Sickness symptoms  0.290***  0.113 
Anxiety  0.248**  0.086 
Neuropsychiatric Comorbidity Factor score  0.202*  0.148 
Neuropsychiatric comorbidity factor was extracted from a principal component 
analysis performed on neuropsychiatric scores. Results are showed as Bravais- 
Pearson correlations performed on the whole population under study. *** p <
0.001; ** p < 0.01; * p < 0.05. Abbreviations: MADRS: Montgomery-Asberg 
Depression Rating Scale; MFI: Multidimensional Fatigue Inventory; NRS: 
Neurotoxicity Rating Scale; hsCRP: high-sensitive C-reactive protein; hsIL-6: 
high-sensitive interleukin-6. 
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systemic inflammation and neuropsychiatric symptom profiles in a 
sample of individuals stratified by BMI. Findings indicate an overall 
increased neuropsychiatric comorbidity, non-specific to symptom di-
mensions/profiles, related obesity degrees and systemic inflammation in 
subjects afflicted with obesity. Accordingly, MDD was found to be more 
prevalent in subjects with severe or very severe obesity compared to lean 
controls. Albeit there was no significant difference between severe and 
very severe obesity with regard to prevalence of MDD, severely obese 
subjects tended to exhibit higher rates. In line with this, MADRS scores 
were greater in subjects with severe obesity, notably in items assessing 
sadness, inability to feel, pessimistic and suicidal thoughts. Fatigue and 
sickness symptoms, assessed with the MFI and NRS respectively, were 
also found to be more severe in subjects with severe obesity compared to 
lean controls. Nevertheless, these symptoms were also apparent in 
subjects with overweight or moderate obesity (physical fatigue) and in 
subjects with very severe obesity (physical fatigue and sickness symp-
toms). Strong associations were found between obesity-related depres-
sive symptoms, fatigue and general neurobehavioral symptoms, 
providing new insights on the phenomenology of neuropsychiatric 
symptoms developing in obese subjects. The subtle, but constant, 
exacerbation of neuropsychiatric symptoms in subjects with severe 
obesity compared to very severe obesity is also noteworthy. Whereas 
further investigations are needed to elucidate the reason for this finding, 
differences in the history/anteriority of obesity in the two groups may be 
involved. Indeed, and consistent with previous studies (Wrzosek et al., 
2018), most of subjects with very severe obesity were obese since 
childhood/adolescence, whereas the proportions early-onset obesity 
versus late-onset obesity were equal in the group of severely obese 
subjects. Accordingly, it may be that long-term obesity is associated with 
the development, over time, of psychological compensatory or adjust-
ment strategies that could moderate the impact of obesity on psycho-
logical wellbeing (Puhl and Brownell, 2006). This possibility merits to 
be assessed in future studies. 
In line with previous reports (Park et al., 2005; Capuron et al., 2011; 
Delgado et al., 2018), we found strong associations between adiposity 
and systemic inflammation, reflected in higher hsCRP and hsIL-6 in the 
groups of obese subjects. While hsCRP levels were primarily increased in 
subjects with severe and very severe obesity relatively to subjects with 
overweight or moderate obesity and lean controls, hsIL-6 levels were 
steadily increased in all obese groups, regardless of obesity severity. Of 
note, no significant difference was found between subjects with severe 
and very severe obesity and between lean controls and subjects with 
overweight or moderate obesity with respect to hsCRP levels. Consistent 
with previous data and supporting the role of inflammation in obesity- 
related neuropsychiatric symptoms (Capuron et al., 2011; Delgado 
et al., 2018; Lasselin et al., 2016; Shelton et al., 2015), hsCRP and hsIL-6 
were individually correlated with neuropsychiatric comorbidities in the 
whole population under study. Associations were stronger for hsCRP 
that correlated significantly with a large number of neuropsychiatric 
parameters including depression scores, physical fatigue, sickness and 
anxiety. HsIL-6 was primarily associated with symptoms of physical 
fatigue and reduced activity. In line with this, increased neuropsychi-
atric comorbidity was associated with higher levels of inflammation, in 
particular hsCRP, in both correlational and cross-sectional analyses. The 
specific associations found between hsCRP and hsIL6 with neuropsy-
chiatric symptoms were consistent with the differential concentration 
profiles of these two markers per BMI categories. In particular, the fact 
that hsCRP was preferentially associated with neuropsychiatric symp-
toms was coherent with the similarity of distribution of both hsCRP 
levels and neuropsychiatric symptoms along obesity severity degrees. 
Similarly, hsIL6 concentrations, which were already increased in low 
grades of obesity, correlated preferentially with non-specific symptoms 
(e.g., physical fatigue) that were apparent in all obese subjects, 
regardless of obesity severity degrees. Altogether, these findings support 
the involvement of low-grade inflammation in obesity-related neuro-
psychiatric comorbidity. They suggest that strategies aiming at reducing 
systemic inflammation could be relevant to improve neuropsychiatric 
status and reduce the risk of depression in subjects with increased 
adiposity. Consistent with this notion, weight-loss interventions, 
including bariatric surgery, were found to simultaneously reduce sys-
temic inflammation, emotional distress and depressive symptoms in 
severely obese subjects (Capuron et al., 2011; Emery et al., 2007). 
The present study includes limitations that future investigations 
should overcome. Although BMI represents the most common measure 
of obesity, this index is not fully representative of body fat distribution, 
notably central adiposity. Compared to the subcutaneous adipose tissue, 
the visceral adipose tissue is considered as being a more reliable deter-
minant of obesity-related comorbidities. Accordingly, it could be more 
relevant than BMI with respect to adiposity-related inflammation and its 
relationship with neuropsychiatric symptoms consistent with data 
showing associations between central/abdominal adiposity (e.g., waist 
circumference, waist-to-hip ratio), inflammation and depressive symp-
toms (Everson-Rose et al., 2009). Additional measures of fat distribution 
could help addressing this issue so as to ultimately improve the identi-
fication of obese individuals with greater risk of neuropsychiatric co-
morbidity. It may also be interesting to add assessments of markers 
involved in the promotion of inflammation, including gut microbiota, 
endotoxemia, and oxidative stress markers, whose implication in the 
pathophysiology of neuropsychiatric symptoms has raised significant 
interest over the last years. Moreover, albeit results were systematically 
controlled for gender, the high prevalence of women among participants 
from this study may represent another limitation given the known in-
fluence of gender on the association between inflammation and 
depression (Köhler-Forsberg et al., 2017; Vetter et al., 2013). In addi-
tion, the small and unequal size of study groups may have contributed to 
reduce the statistical power for detection of significant associations. 
Finally, the cross-sectional design of the present study does not allow the 
establishment of a temporal or causal relationship between adiposity- 
related inflammation and neuropsychiatric symptoms. Large longitudi-
nal studies should be performed to specifically address this issue. 
In conclusion, this study provides a detailed picture of the relation-
ship between neuropsychiatric symptoms and inflammatory status, ac-
cording to obesity severity grades. It shows that obesity is characterized 
by inter-related neuropsychiatric symptoms, including depression, fa-
tigue and general behavioral symptoms, together with a chronic low- 
grade inflammatory state that augment with adiposity degrees. The 
significant linear association found between adiposity degrees, systemic 
inflammation and neuropsychiatric alterations strongly supports the 
involvement of adiposity-related inflammatory processes in neuropsy-
chiatric comorbidities. These data provide new insight on the phe-
nomenology of neuropsychiatric symptoms developing in contexts of 
obesity. They suggest that the consideration of adiposity characteristics 
may help to identify subjects with an increased risk of neuropsychiatric 
comorbidity and to improve the management/treatment of specific 
subgroups of patients afflicted with neuropsychiatric symptoms (Shelton 
et al., 2015). They point to hsCRP as a relevant biomarker of adiposity- 
Table 5 
Association of neuropsychiatric comorbidity with adiposity-related systemic 
inflammation.   
Neuropsychiatric Comorbidity   
Negative 
n = 91 
Positive 
n = 69 
p1 p2 
Log hsCRP 0.41 (0.58) 0.64 (0.52)  0.009  0.025 
Log hsIL-6 0.13 (0.31) 0.22 (0.22)  0.041  0.047 
Participants were stratified on the basis of their scores on the neuropsychiatric 
comorbidity factor extracted from the principal component analysis performed 
on neuropsychiatric scores. Data are shown as mean (+ SEM) compared by 
Student t-test (p1) or ANCOVA controlling for age, gender and comorbidities 
(p2), performed on the whole population under study. Abbreviations: hsCRP: 
high-sensitive C-reactive protein; hsIL-6: high-sensitive interleukin-6; SEM: 
standard error of the mean. 
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related neuropsychiatric symptoms that could help orienting clinical 
assessment/practice and guiding innovative and personalized treatment 
strategies targeting inflammatory processes in depressed patients with 
obesity. 
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